Novo Holdings, the controlling shareholder of weight loss drugmaker Novo Nordisk A/S (NYSE:NVO), reported Wednesday income and investment returns of 60 billion Danish kroner (around $8.68 billion) for ...

While gastrointestinal issues are the most common side effects, a recent study by the University of British Columbia linked ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Artisan Partners, an investment management company, released its “Artisan Global Opportunities Fund” fourth quarter 2024 ...

President Trump has announced sweeping tariffs on several countries. Novo Nordisk and Smith & Nephew may be the most at risk ...

The line-up consists of supplements to meet the health needs to patients taking GLP-1 medications for weight loss.

Here's everything you need to know about the new weight loss medication being rolled out by the NHS to treat obesity.

(Reuters) -KKR has abandoned a private equity consortium discussing a takeover of Gerresheimer AG, Bloomberg News reported on ...

Originally developed to treat Type 2 diabetes, glucagon-like peptide 1 (GLP-1s) are now being studied to explore their ...

Dividend stocks have been a reliable cornerstone for those who want to anchor their portfolios when markets get shaky. These ...